Results 121 to 130 of about 18,162 (243)

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review [PDF]

, 2022
Claire L Townsend, John O’Rourke, Edith B. Milanzi, Intira Jeannie Collins, Ali Judd, Hannah Castro, Marissa Vicari, Julie Jesson, Valériane Leroy, Françoise Renaud, Martina Penazzato   +10 more
openalex   +1 more source

‘How much raltegravir do you take?’ The answer may not be so obvious: an accidental finding from clinical practice [PDF]

, 2019
Arianna Emiliozzi, Arturo Ciccullo, Alberto Borghetti, Chiara Picarelli, Damiano Farinacci, Gianmaria Baldin, Simona Di Giambenedetto   +6 more
openalex   +1 more source

Predicting intestinal absorption of raltegravir using a population-based ADME simulation [PDF]

, 2013
Darren Moss, Marco Siccardi, David Back, Andrew Owen   +3 more
openalex   +1 more source

Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir [PDF]

, 2016
Florin Tuluc, Sergei Spitsin, Nancy B. Tustin, Jennifer B. Murray, R. Don Tustin, Laura A. Schankel, Andrew Wiznia, Sharon Nachman, Steven D. Douglas   +8 more
openalex   +1 more source

Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART [PDF]

, 2015
Peer reviewedPublisher ...
Baguley, Steve, Brawley, Daniela, Butt, Ambreen, Ismail, Muhammad A, Okpo, Emmanuel, Tonna, Ivan   +5 more
core  

Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs

Качественная клиническая практика, 2018
Objective: To perform comprehensive pharmacoeconomical assessment of use etravirine and raltegravir in HIV-infected patients. Methodology: Cost-eifectiveness and budget impact analyses of etravirine or raltegravir on the top of optimized background ...
Y. I. Ashikhmin, D. Yu. Belousov
doaj  

Raltegravir: first in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj  

Raltegravir [PDF]

, 2020
openaire   +1 more source

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study [PDF]

, 2017
Background Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) >50 copies/mL. Methods The protease and reverse transcriptase (RT) genes were systematically sequenced in samples from 756 patients with VL >50 copies/mL in ...
Assoumou, Lambert, Chaix, Marie-Laure, Costagliola, Dominique, Delaugerre, Constance, Descamps, Diane, Dos Santos, Georges, Izopet, Jacques, Marcelin, Anne-Geneviève, Masquelier, Bernard, Montes, Brigitte, Morand-Joubert, Laurence, Pakianather, Sophie, Plantier, Jean-Christophe, Ruffault, Annick, Wirden, Marc, Yerly, Sabine   +15 more
core  

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women [PDF]

, 2010
Matt S. Anderson, William D. Hanley, Allison Moreau, Bo Jin, Frederick A. Bieberdorf, James Kost, Larissa Wenning, Julie A. Stone, John A. Wagner, Marian Iwamoto   +9 more
openalex   +1 more source